IQVIA Holdings, Inc.
IQV
$207.32
+4.43%
IQVIA Holdings Inc. is a global leader in clinical research and technology solutions for the life science industry, formed in 2016 from the merger of Quintiles and IMS Health. It combines outsourced clinical development services with extensive healthcare data and analytics, serving biopharmaceutical firms, providers, payers, and policymakers. The current investor narrative centers on the company's ability to sustain revenue growth amid a dynamic biotech funding environment, with recent focus on its Research and Development Solutions segment and margin expansion initiatives. Attention is also drawn to analyst upgrades and the stock's recovery from a significant drawdown earlier in 2026.…
IQV
IQVIA Holdings, Inc.
$207.32
Related headlines
Investment Opinion: Should I buy IQV Today?
Rating: Buy. IQVIA offers a compelling risk/reward with accelerating revenue growth, margin expansion, and a discounted valuation vs. its own history, supported by a consensus Strong Buy rating and average target of $232.00 (12.5% upside).
Supporting evidence: (1) Revenue growth accelerated to 8.4% YoY in Q1 2026, up from 4.0% a year ago. (2) Trailing P/E of 28.5x is below the 5-year average of 35x, suggesting value. (3) Gross margin improved from 27.7% in Q2 2024 to 32.6% in Q1 2026. (4) TTM free cash flow of $2,545 million provides financial flexibility. The forward P/E of 14.6x implies strong earnings growth, and the stock trades at a discount to its historical multiple.
Risks & Conditions: The biggest risks are high leverage (debt-to-equity 2.49x) and a premium to industry P/E (28.5x vs. 22.0x). This Buy rating would be downgraded to Hold if revenue growth decelerates below 6% or if the trailing P/E expands above 35x without earnings acceleration. Upgrade to Strong Buy if growth sustains above 10% and margins continue expanding. Overall, IQVIA appears fairly valued relative to its history but slightly overvalued vs. peers, with the growth trajectory justifying the premium.
Sign up to view all
IQV 12-Month Price Forecast
IQVIA's accelerating revenue growth, margin expansion, and discounted valuation relative to its history support a bullish stance. The consensus Strong Buy rating and 12.5% upside to the average target reinforce positive sentiment. However, high leverage and a premium to industry peers temper confidence to medium. Key developments to watch are sustained revenue growth above 8% and margin improvement. If growth decelerates or leverage becomes a concern, the stance would shift to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IQVIA Holdings, Inc.'s 12-month outlook, with a consensus price target around $232.00 and implied upside of +11.9% versus the current price.
Average Target
$232.00
0 analysts
Implied Upside
+11.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $284
Analyst target range
IQVIA is covered by 19 analysts, with a consensus recommendation of 'Strong Buy' (mean 1.45 on a 1-5 scale). The average target price is $232.00, implying an upside of 12.5% from the current price of $206.26. The distribution shows 16 Buy, 2 Hold, and 1 Sell, reflecting strong bullish sentiment. The target range spans from $200.00 (low) to $284.00 (high), with the high target suggesting potential upside of 37.7% if the company achieves accelerated growth or multiple expansion. The low target of $200.00 implies a modest downside of 3.0%, indicating limited bearish risk. Recent upgrades from TD Cowen (Hold to Buy) and Barclays (Equal Weight to Overweight) in March 2026 reinforce positive momentum, while Morgan Stanley's downgrade from Overweight to Equal Weight in June 2026 adds a note of caution.
Bulls vs Bears: IQV Investment Factors
IQVIA presents a balanced risk/reward profile. The bull case is supported by accelerating revenue growth, margin expansion, a discounted valuation vs. history, and strong free cash flow, backed by a consensus Strong Buy rating with 12.5% upside. However, the bear case highlights elevated leverage, tight liquidity, a premium vs. industry peers, and mixed analyst sentiment. The single most important tension is whether IQVIA can sustain its revenue growth acceleration above 8% YoY, as this would justify its premium valuation and drive multiple expansion. If growth decelerates, the stock could face compression toward the low target of $200. Currently, the bull case has slightly stronger evidence given the accelerating growth and discounted historical valuation.
Bullish
- Strong Buy Consensus with 12.5% Upside: IQVIA has a consensus rating of Strong Buy (mean 1.45) from 19 analysts, with an average target price of $232.00, implying 12.5% upside from the current $206.26. The high target of $284.00 suggests potential 37.7% upside if growth accelerates.
- Revenue Growth Accelerating to 8.4%: Q1 2026 revenue grew 8.4% YoY to $4,151 million, accelerating from 4.0% growth in Q1 2025. This indicates strong demand for clinical trial services and technology solutions, driven by biotech funding recovery.
- Margin Expansion Trend: Gross margin improved from 27.7% in Q2 2024 to 32.6% in Q1 2026, reflecting operational efficiencies. Operating margin of 12.4% is stable, and net margin of 6.6% shows profitability despite interest expenses.
- Discounted Valuation vs. History: Trailing P/E of 28.5x is below the 5-year average of 35x, suggesting the stock is undervalued relative to its own history. Forward P/E of 14.6x implies significant earnings growth, offering a compelling entry point.
Bearish
- Elevated Debt-to-Equity of 2.49x: IQVIA's debt-to-equity ratio of 2.49x is high, indicating significant leverage. Interest expense of $192 million in Q1 2026 weighs on net income, and a rising rate environment could pressure earnings further.
- Current Ratio Below 1.0 at 0.75x: A current ratio of 0.75x suggests tight liquidity, meaning current liabilities exceed current assets. While operating cash flow is strong, any disruption could strain short-term obligations.
- Revenue Growth Deceleration Trend: Despite Q1 2026 acceleration, multi-quarter trend shows deceleration from 8.4% in Q1 2026 to 4.0% in Q1 2025. Sustaining growth above 8% may be challenging if biotech funding softens.
- Premium Valuation vs. Industry Peers: Trailing P/E of 28.5x is 30% above the estimated industry average of 22.0x. If growth disappoints, multiple compression could erase the premium, leading to downside.
IQV Technical Analysis
IQVIA's stock has experienced a volatile year, with a 1-year price change of +26.3%, but the path has been far from smooth. The current price of $206.26 sits at 46% of its 52-week range ($154.50 low to $247.05 high), indicating the stock is closer to the lower end of its range after a sharp decline earlier in 2026. This positioning suggests the stock is in a recovery phase from its February lows, but still well below the highs, implying potential upside if momentum continues or a risk of renewed weakness if resistance holds. The 52-week high of $247.05 represents a key resistance level, while the low of $154.50 serves as critical support.
Beta
1.20
1.20x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$155-$247
Price range past year
Annual Return
+6.7%
Cumulative gain past year
| Period | IQV Return | S&P 500 |
|---|---|---|
| 1m | +21.0% | +0.6% |
| 3m | +27.8% | +3.4% |
| 6m | -11.9% | +7.1% |
| 1y | +6.7% | +16.4% |
| ytd | -8.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IQV Fundamental Analysis
IQVIA's revenue trajectory shows steady growth, with Q1 2026 revenue of $4,151 million up 8.4% year-over-year, accelerating from the 4.0% growth in Q1 2025. The Research and Development Solutions segment contributed $2,397 million, indicating strong demand for clinical trial services. However, the multi-quarter trend shows deceleration from 8.4% in Q1 2026 to 4.0% in Q1 2025, suggesting a need for sustained momentum. The company is profitable, with Q1 2026 net income of $274 million and a gross margin of 32.6%, which has improved from 27.7% in Q2 2024. Operating margin of 12.4% is stable, but net margin of 6.6% reflects the impact of interest expenses. IQVIA maintains a healthy balance sheet with free cash flow of $2,545 million TTM, though debt-to-equity of 2.49x is elevated. The current ratio of 0.75x indicates tight liquidity, but strong operating cash flow of $618 million in Q1 2026 supports internal funding of growth.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
32.6%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IQV Overvalued?
Since net income is positive, the trailing P/E ratio of 28.5x is the primary valuation metric. The forward P/E of 14.6x implies a significant earnings growth expectation, with the gap suggesting the market anticipates a sharp increase in earnings. Compared to the industry average P/E of 22.0x (estimated), IQVIA trades at a 30% premium, reflecting its market leadership and growth profile. Historically, the current trailing P/E of 28.5x is below the 5-year average of 35x, indicating the stock is trading at a discount to its own historical valuation, which could signal a value opportunity if fundamentals remain strong.
PE
28.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IQVIA's high debt-to-equity ratio of 2.49x and interest expense of $192 million per quarter create earnings vulnerability to rising interest rates. The current ratio of 0.75x indicates tight liquidity, though strong operating cash flow of $618 million in Q1 2026 mitigates near-term risk. Revenue concentration in the Research and Development Solutions segment ($2,397 million in Q1 2026) exposes the company to biotech funding cycles, which can be volatile. Net margin of 6.6% is modest, leaving limited buffer for cost shocks.
Market & Competitive Risks: IQVIA trades at a trailing P/E of 28.5x, a 30% premium to the industry average of 22.0x, making it susceptible to valuation compression if growth slows. The stock's beta of 1.2 indicates above-average market correlation, amplifying downside during broad selloffs. Competitive threats include in-house capabilities at large pharma and rivals like Labcorp. Recent news about Eli Lilly's weight-loss pill struggles (April 2026) highlights biotech sector volatility, which could impact IQVIA's client spending.
Worst-Case Scenario: A sharp downturn in biotech funding, combined with rising interest rates, could cause IQVIA's revenue growth to decelerate below 4%, triggering multiple compression. In this scenario, the stock could fall to its 52-week low of $154.50, representing a 25.1% decline from the current price of $206.26. The historical max drawdown of -35.87% suggests even deeper losses are possible in severe downturns.
FAQ
The key risks are: (1) Financial risk from high leverage (debt-to-equity 2.49x) and interest expense of $192 million quarterly, which could pressure earnings if rates rise. (2) Valuation risk from a 30% premium to the industry P/E, making the stock vulnerable to multiple compression if growth disappoints. (3) Macro risk from biotech funding cycles, as a downturn could slow revenue growth below 4%. (4) Competitive risk from in-house R&D at large pharma or rivals like Labcorp. The most severe risk is a funding freeze that could drive the stock to its 52-week low of $154.50, a 25% decline from current levels.
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $232-$284, driven by sustained revenue growth above 10% and multiple expansion. Base case (50% probability) targets $200-$232, with 7-8% growth and steady margins. Bear case (20% probability) targets $154.50-$200, if growth decelerates below 4%. The most likely scenario is the base case, assuming biotech funding remains stable and IQVIA delivers 7-8% revenue growth, leading to a price near the analyst average target of $232.
IQVIA's trailing P/E of 28.5x is below its 5-year historical average of 35x, indicating it is undervalued relative to its own history. However, compared to the industry average P/E of 22.0x, it trades at a 30% premium, suggesting it is overvalued versus peers. The forward P/E of 14.6x implies the market expects significant earnings growth, which could justify the premium if realized. Overall, IQV appears fairly valued when considering its growth trajectory and historical multiples, but it is not a deep value play.
IQVIA presents a compelling buy opportunity given its accelerating revenue growth (8.4% YoY in Q1 2026), margin expansion (gross margin up from 27.7% to 32.6% in two years), and a consensus Strong Buy rating with 12.5% upside to the average target of $232. The trailing P/E of 28.5x is below its 5-year average of 35x, suggesting value. However, high debt (debt-to-equity 2.49x) and a premium to the industry P/E of 22.0x introduce risk. For investors with a moderate risk tolerance and a 12-month horizon, IQV is a good buy, but those seeking lower volatility may prefer to wait for a pullback closer to $200.
IQVIA is best suited for a long-term investment horizon of 3-5 years, given its secular growth drivers in clinical research outsourcing and healthcare data analytics. The stock's beta of 1.2 indicates moderate volatility, and its recovery from a 35.87% drawdown shows potential for sharp swings, making it less ideal for short-term trading. The company does not pay a dividend, so returns rely on capital appreciation. With strong free cash flow and a discounted historical valuation, long-term investors can benefit from compounding growth, but they must tolerate cyclical biotech funding risks.